Application of pinostrobin in preparation of xanthine oxidase inhibition drugs
By isolated ethyl acetate extract from dal leaf lipozolin as a xanthine oxidase inhibitor, the problems of low efficiency and major side effects of existing drugs have been solved, and efficient inhibition of xanthine oxidase has been achieved. Provides safer and more effective treatment options for hyperuricemia.
Patent Information
- Application Number
- CN202411342967.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-11-12
AI Technical Summary
Existing xanthine oxidase inhibitors such as allopurinol are inefficient in treatment and have great side effects. Febulista may increase the risk of death from cardiovascular disease, and new xanthine oxidase inhibitors are needed to replace existing drugs.
Glosonecin was isolated, purified and identified from the ethyl acetate extract of dal leaf. It was found that it had the strongest inhibitory activity on xanthine oxidase, with an IC50 of 16.07μM, and it was determined by in vitro experiments that it was reversible competitive inhibition. Agent, used in the preparation of xanthine oxidase inhibitors.
As an active ingredient, citrusin can effectively inhibit xanthine oxidase, provide more efficient treatment and prevention of hyperuricemia, reduce side effects, and is suitable for the treatment of hyperuricemia, gout, diabetes and other related diseases.
Smart Images

Figure CN118924734A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of natural product medicines, and in particular relates to the application of pinostrobin in the preparation of xanthine oxidase inhibitory drugs. Background Art
[0002] Hyperuricemia (fasting blood uric acid levels on two different days: >420umol / L for men and >360umol / L for women) is a metabolic disease caused by decreased excretion or increased production of serum uric acid. Hyperuricemia can not only cause gout, but also damage organs such as the kidneys and blood vessels. Therefore, the development of drugs for the treatment of hyperuricemia is urgent.
[0003] Xanthine oxidoreductase (XO) is a key enzyme in purine metabolism that catalyzes the oxidation of xanthine to uric acid. Therefore, XO is an important target for drugs to treat hyperuricemia. Clinically, inhibitory drugs for XO include febuxostat and allopurinol. However, the therapeutic efficiency of allopurinol is less than 50%, and it will also cause a certain degree of liver and kidney damage to patients, accompanied by side effects such as rash and fever. Febuxostat has a more effective XO inhibitory effect than allopurinol, but recent clinical studies have found that it may increase the risk of death from cardiovascular disease. Therefore, it is necessary to develop new XO inhibitors.
[0004] Many medicinal and edible plants have been shown to alleviate hyperuricemia by inhibiting XO. For example, ethanol extract of marigold leaves can inhibit liver XO activity and significantly reduce hyperuricemia; a mixture of chrysanthemum and cinnamon extracts exerts anti-hyperuricemia effects by inhibiting XO activity and uric acid reabsorption. Pigeon pea (Cajanus cajan(l)Millsp) is an important leguminous food crop grown in more than 80 countries. Pigeon pea has a variety of pharmacological activities, including the treatment of chronic infections, wound healing, gynecological diseases, avascular necrosis of the femoral head, diabetes, stomach pain, ischemic heart disease, gingivitis, etc. Summary of the invention
[0005] The present invention proposes the application of pinosporin in preparing xanthine oxidase inhibitory drugs based on the discovered new function of pinosporin (i.e., inhibiting xanthine oxidase activity).
[0006] Previous studies have found that the ethyl acetate extract of pigeon pea leaves has strong xanthine oxidase inhibitory activity, but its active substance is still unclear. The present invention separates, purifies and identifies the active substances of the ethyl acetate extract of pigeon pea leaves, and obtains a total of 16 flavonoids, 10 stilbenes and 4 other types of compounds. Through in vitro xanthine oxidase inhibition experiments, it was found that among these 30 compounds, pinospermum officinale has the strongest inhibitory activity on xanthine oxidase, and its half inhibition concentration IC 50The inhibitory kinetics analysis showed that the inhibition type of pinospermum officinale on xanthine oxidase was reversible competitive inhibition.
[0007] In view of the strong xanthine oxidase inhibitory activity of pinospermum indole, it can be used to prepare xanthine oxidase inhibitory drugs or preventive or therapeutic drugs for xanthine oxidase-related diseases.
[0008] Therefore, the present invention provides the use of pinospermum in the preparation of xanthine oxidase inhibitory drugs;
[0009] The chemical structural formula of pinospermum camphor is shown in Formula 1:
[0010]
[0011] Preferably, the xanthine oxidase inhibitor is prepared from pinostrobin or a pharmaceutically acceptable salt thereof as an active ingredient and other pharmaceutical excipients or carriers.
[0012] Preferably, the xanthine oxidase inhibitor is a drug for treating or preventing diseases related to xanthine oxidase activity, including but not limited to hyperuricemia, gout, diabetes, kidney disease, cardiovascular disease, etc. More preferably, the xanthine oxidase inhibitor is a drug for treating hyperuricemia.
[0013] Preferably, the medicine can be any one or more of granules, capsules, tablets, powders, pills, sustained-release preparations or injections.
[0014] The present invention also provides a xanthine oxidase inhibitory drug, which contains the pinostrobin as an active ingredient.
[0015] The present invention found that the ethyl acetate extract of pigeon pea leaves has good xanthine oxidase inhibitory activity. Subsequently, we separated and purified the active substances from the ethyl acetate extract, and obtained a total of 16 flavonoids, 10 stilbenes and 4 other types of compounds. Further evaluation of the xanthine oxidase inhibitory activity of these compounds revealed that pinospermum officinale was the compound with the strongest inhibitory activity, with an IC 50 The concentration of xanthine oxidase inhibitor is 16.07 μM, which can be used to prepare xanthine oxidase inhibitory drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 It is the chemical formula of the monomer compound identified in the ethyl acetate extract of pigeon pea leaves;
[0017] Figure 2 The inhibitory activity of 30 identified compounds on xanthine oxidase is measured. (A) The inhibition curve of compound 12 (i.e. pinospermum officinale) on xanthine oxidase; (B) The inhibition rate of 60 μM compound on xanthine oxidase;
[0018] Figure 3 This is an analysis of the inhibition type of pinosprolin on xanthine oxidase. (A) The inhibition type of pinosprolin (PSB) on xanthine oxidase; (B) The double reciprocal curve of pinosprolin's inhibition of xanthine oxidase. DETAILED DESCRIPTION
[0019] The following examples are provided to further illustrate the present invention, rather than to limit the present invention.
[0020] Example 1: Isolation, purification and identification of active substances in ethyl acetate extract of pigeon pea
[0021] (1) Experimental methods
[0022] 30.0 kg of dried and crushed pigeon pea leaves were extracted with 95% ethanol at room temperature and distilled under reduced pressure to obtain 5.0 kg of crude extract. The extract was mixed with water to form a suspension and then extracted with acetone, ethyl acetate, n-hexane and methanol respectively. The ethyl acetate extract obtained was used for subsequent separation and purification of active substances. The compounds were identified by 1D and 2D NMR.
[0023] (2) Experimental results
[0024] like Figure 1 As shown in the figure, 16 flavonoids (compounds 1 to 16), 10 stilbenes (compounds 17 to 26) and 4 other types (compounds 27 to 30) were identified from the ethyl acetate extract of pigeon pea leaves. Among them, pinospermum officinale (compound 12) has a molecular formula of C 16 H 14 O4, colorless crystals; NMR spectrum: 1 H NMR (500 MHz, CDCl3): δ H 2.02 (1H, s, 5-OH), 7.56-7.32 (5H, m, H-2′, 3′, 4′, 5′, 6′), 6.08 (2H, dd, J=7.0, 2.3Hz, H-6, 8), 5.43 (1H, dd, J=13 .0, 3.0Hz, H-2), 3.81 (3H, s, 7-OCH3), 3.09 (1H, dd, J=17.2, 13.0Hz, H-3α), 2.83 (1H, dd, J=17.2, 13.0Hz, H-3β). 13 C NMR (125 MHz, CDCl3): δ C195.6(C-4), 167.8(C-7), 164.0(C-5), 162.7(C-9), 138.3(C-1′), 128.7(C-3′, 4′, 5′), 126 .0(C-2′, 6′), 103.0(C-10), 95.0(C-6), 94.1(C-8), 79.1(C-2), 55.6(7-OCH3), 43.3(C-3).
[0025] Example 2: Determination of Xanthine Oxidase Inhibitory Activity of Monomeric Compounds of Pigeon Pea Ethyl Acetate Extract
[0026] (1) Reagent preparation
[0027] 0.01M phosphate buffer (PBS): weigh 8g NaCl, 0.2g KCl, 1.44g Na2HPO4 and 0.24g KH2PO4, dissolve in 900ml distilled water, adjust the pH to 7.4 with HCl, finally add distilled water to 1L, filter and sterilize.
[0028] Preparation of xanthine oxidase (XO) solution: Weigh 2 mg xanthine oxidase (100 U), add 10 mL PBS to prepare a 10 U / mL stock solution, and then dilute the stock solution to obtain a 0.5 U / mL enzyme working solution.
[0029] Preparation of xanthine substrate: weigh 0.06g of NaOH, add 8mL of distilled water, and then add 0.057g of xanthine to obtain xanthine sodium hydroxide solution (liquid A). Weigh 0.27g of potassium dihydrogen phosphate and add 10mL of distilled water to obtain liquid B. Mix liquid A and liquid B and adjust the volume to 40mL to obtain liquid C. Take 10mL of liquid C and add 15mL of PBS buffer to obtain liquid D. Take 1mL of liquid D and add 7.33mL of PBS buffer to obtain a 1mmol / L xanthine substrate solution.
[0030] (2) Experimental methods
[0031] Take 110 μL PBS buffer and add it to the 96-well UV ELISA plate. Add 110 μL to the first row of wells. Figure 1 The compound dissolved in PBS was diluted to row 7 by two-fold gradient. Then 30 μL of xanthine oxidase was added, incubated at 25°C in the dark for 15 min, and then 60 μL of xanthine substrate solution was added. The absorbance at 295 nm was measured at room temperature as A. The corresponding blank control group was a group in which 30 μL of xanthine oxidase was replaced with 30 μL of PBS buffer, and the absorbance was B. The reaction system without inhibitors was the control group, and the absorbance was C. The corresponding blank control group absorbance was D. Xanthine oxidase inhibition rate = [(CD)-(AB)] / (CD). Three technical replicates were performed for each sample.
[0032] (3) Experimental results
[0033] The final concentrations of the 30 compounds isolated were set to 60, 30, 15, 7.5, 3.75, 1.875, and 0.9375 μM, respectively, among which only compound 12 (i.e., pinospermum officinale) showed strong concentration-dependent xanthine oxidase inhibitory activity. Figure 2 As shown in A, the inhibitory activity curve of pinospermum camphora on xanthine oxidase is y=19.189ln(x)-3.2851 (x represents drug concentration, y represents inhibition rate), and the half inhibition concentration IC 50 is 16.07μM. Figure 2 As shown in Figure B, among the 30 compounds tested, compounds 4, 5, 8, 13, 15, 16, 17, 18, 19, 21, 22, 25, and 28 had weak inhibitory activity at 60 μM, while the xanthine oxidase inhibition rate of pinospermum parkin (i.e., compound 12) reached 82.25±1.80%, and no xanthine oxidase inhibitory activity was detected for other compounds.
[0034] Example 3: Kinetic analysis of the inhibition of xanthine oxidase by pinospermum officinale
[0035] (1) Experimental methods
[0036] In the reaction system of pinosprolin and enzyme, the substrate concentration was fixed at 200 μM. By changing the concentration of xanthine oxidase, the relationship between the absorbance change rate and the XO concentration was measured in the presence of different concentrations of pinosprolin. The inhibition type of pinosprolin on XO was determined based on its changing trend.
[0037] In the reaction system of pinospermum officinale and enzyme, the concentration of xanthine oxidase was fixed at 0.3U / mL, and the relationship between the reaction rate and the xanthine substrate concentration in the presence of different concentrations of pinospermum officinale was determined. The Michaelis-Menten equation curve was drawn using the double reciprocal plotting method.
[0038] (2) Experimental results
[0039] like Figure 3 As shown in A, the relationship between the product production rate and the concentration of xanthine oxidase XO is a straight line passing through the origin with a decreasing slope, indicating that the inhibitory effect of pinospermum officinale on xanthine oxidase is a reversible inhibition type. Figure 3 As shown in B, the double reciprocal plotting method is used to draw the relationship curve between the reciprocal of the reaction rate and the reciprocal of the xanthine substrate concentration. The greater the concentration of pinospermum sphaeroides, the smaller the horizontal intercept, while the vertical intercept remains unchanged, indicating that pinospermum sphaeroides competitively inhibits xanthine oxidase.
Claims
1. Application of pinospermum in the preparation of xanthine oxidase inhibitors; The chemical structural formula of pinospermum camphor is shown in Formula 1:
2. The use according to claim 1, characterized in that: The xanthine oxidase inhibitory drug is prepared by taking pinostrobin or its pharmaceutically acceptable salt as active ingredient and other drug excipients or carriers.
3. The use according to claim 1, characterized in that: The xanthine oxidase inhibitory drug is a drug for treating or preventing diseases related to xanthine oxidase activity, including but not limited to hyperuricemia, gout, diabetes, kidney disease, cardiovascular disease, etc.
4. The use according to claim 3, characterized in that: The xanthine oxidase inhibitor is a drug for treating hyperuricemia.
5. The use according to claim 1, characterized in that: The medicine is any one or more of granules, capsules, tablets, powders, pills, sustained-release preparations or injections.
6. A xanthine oxidase inhibitory drug, characterized in that: Contains pinostrobin as an active ingredient.
Citation Information
Cited By
Application of pigeonpea extract and active ingredients in relieving hyperuricemia
CN120789121A
